publication date: Jan. 10, 2020
ALK Positive and LUNGevity issue RFA for 2020 ALK-positive Lung Cancer Research Award Program
ALK Positive/LUNGevity is requesting applications for the 2020 ALK-positive Lung Cancer Research Award. Letters of intent are due Feb. 14.
Funded projects are expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission.
The ALK-positive award is open to researchers at United States and international institutions.
At the time of application, an international candidate must name a co-principal investigator who is employed at a U.S. institution.
This award is in addition to the LUNGevity Career Development Award. Information for those awards will be announced separately.
There are two award mechanisms:
The successful applicant may receive up to $500,000 over an award term of two years for the Transformational Award.
Clinical Trial Innovation Award.
The successful applicant may receive up to $750,000 over an award term of two years for the Clinical Trial Innovation Award.
For complete information and instructions, visit http://www.LUNGevity.org/ALK-RFA or proposalcentral.com beginning Jan. 13, 2020. Direct any questions to Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.